Social & QoL Behaviors in Parkinson's Disease

February 11, 2026 updated by: Gregory Wallace

Social Behaviors and Quality of Life in Individuals With Parkinson's Disease

Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Gregory Wallace, PhD
  • Phone Number: 202-994-8285
  • Email: ladn@gwu.edu

Study Locations

  • United States
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20052
        • Recruiting
        • The George Washington University
        • Contact:
          • Gregory Wallace, PhD
          • Phone Number: 202-994-8285
          • Email: ladn@gwu.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study includes both 40+ year old adults with Parkinson's disease and 40+ year old neurotypical adults

Description

Parkinson's disease group

Inclusion Criteria:

  • Have been diagnosed with Parkinsons Disease by a healthcare professional
  • Are at least 40 years old

Exclusion Criteria:

  • Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)

Neurotypical group

Inclusion Criteria:

  • Are at least 40 years old

Exclusion Criteria:

  • Have been diagnosed with Parkinson's disease by a healthcare professional
  • Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Parkinson's disease

This group includes adults who:

  • Have been diagnosed with Parkinsons Disease by a healthcare professional
  • Are at least 40 years old and
  • Do not possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
Other: No Intervention
Observational study with no intervention
Neurotypical adults

This group includes adults who:

  • Are at least 40 years old
  • Do not have a diagnosis of Parkinsons Disease or any form of dementia and
  • Do not have a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
Other: No Intervention
Observational study with no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective Quality of Life
Time Frame: through study completion, an average of 1 year
satisfaction with different aspects of life, such as health and social relationships
through study completion, an average of 1 year
Social Behavior
Time Frame: through study completion, an average of 1 year
ability to interact with others
through study completion, an average of 1 year
Activities of Daily Living
Time Frame: through study completion, an average of 1 year
ability to complete tasks to be independent
through study completion, an average of 1 year
Mental Health
Time Frame: through study completion, an average of 1 year
depression and anxiety symptoms
through study completion, an average of 1 year
Cognition
Time Frame: through study completion, an average of 1 year
memory and executive function challenges and strengths
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gregory Wallace

Investigators

  • Principal Investigator: Gregory Wallace, PhD, George Washington University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 8, 2024

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

April 18, 2024

First Submitted That Met QC Criteria

April 23, 2024

First Posted (Actual)

April 25, 2024

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 11, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCR234859

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Currently, there is no plan to share participant data with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on No Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe